Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 10/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 10/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 7/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130673 | 0.81 | CYP2A6 (0.38) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL13699263 | 0.81 | CYP2D6 (0.39) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL13416007 | 0.77 | HTT (0.45) | CYP2D6CYP2C19CYP2C9CYP1A2CYP19A1 | |
| SCHEMBL266497 | 0.76 | KDM4E (0.64) | CYP2D6CYP2C19CYP2C9CYP1A2CYP19A1 | |
| SCHEMBL10162003 | 0.75 | CYP2A6 (0.70) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL10162362 | 0.74 | KDM4E (0.66) | CYP1A2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL13621245 | 0.73 | DPP4 (0.41) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL12531526 | 0.72 | CYP2A6 (0.72) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL20388926 | 0.72 | PRKCI (0.66) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 | |
| SCHEMBL10160999 | 0.72 | HDAC1 (0.43) | CYP2D6CYP2C19CYP2A6CYP2C9CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| EP-1506214-B1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARM INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2009075923-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-7407942-B2 | 3,6-bridged 9,12-oxolides | EMATA PHARMACEUTICALS, INC (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008019240-A2 | 3, 6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| WO-2008014221-A2 | BRIDGED CARBAMATE MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-7291602-B2 | 11,12-lactone bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | CYP2D6 12/4885CYP2C19 21/4885CYP2A6 22/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2D6 12/4885CYP2C19 21/4885CYP2A6 22/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2D6 12/4885CYP2C19 21/4885CYP2A6 22/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | CYP2D6 61/4885CYP2C19 4/4885CYP2A6 150/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | CYP2D6 3/4885CYP2C19 2/4885CYP2A6 11/4885 |
| US-20080027012-A1 | BRIDGED CARBAMATE MACROLIDES | HDAC6, SI, HDAC3 | CYP2D6 113/4885CYP2C19 11/4885CYP2A6 130/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | CYP2D6 12/4885CYP2C19 21/4885CYP2A6 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.